Jennifer L. McCurtain

Jennifer L. McCurtain

Auto-generated profile, based on publicly available information

Jennifer L. McCurtain

Department of Microbiology & Immunology, University of Minnesota, Minneapolis, MN 55455, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CNChristine E. Nelson
Christine E. Nelson
LMLauren Mills
Lauren Mills
JMJennifer L. McCurtain
Jennifer L. McCurtain
ETEmily A. Thompson
Emily A. Thompson
DSDavis M. Seelig
Davis M. Seelig
VVVaiva Vezys
Vaiva Vezys
Significance: Cancer immunotherapies, such as immune checkpoint blockade, work by stimulating immune cells to kill tumors. Unfortunately, not all patients respond to checkpoint treatment, which also causes autoimmune side effects due to self-reactive immune cell activation. This study uncovers immune subtypes that respond best to this immunotherapy and reveals methods to reinvigorate dysfunctional antitumor immune responses. We show that self-reactive CD8 T cells can be pathogenic or nonresponsive to checkpoint blockade therapy depending on their activation status. In addition, tolerant self-reactive CD8 T cells bear striking similarity to dysfunctional tumor-specific CD8 T cells. Finally, we demonstrate that previously tolerant self-specific CD8 T cells can eliminate aggressive tumors bearing self-antigens without concomitant autoimmunity after robust antigenic vaccination in concert with PD-L1 blockade.

1 March 2019 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JMJennifer L. McCurtain
Jennifer L. McCurtain
AGAdam J. Gilbertsen
Adam J. Gilbertsen
CEClayton Evert
Clayton Evert
BWBryan J. Williams
Bryan J. Williams
RHRyan C. Hunter
Ryan C. Hunter
Purpose. In the cystic fibrosis (CF) airways, Pseudomonas aeruginosa undergoes diverse physiological changes in response to inflammation, antibiotic pressure, oxidative stress and a dynamic bioavailable nutrient pool. These include loss-of-function mutations that result in reduced virulence, altered metabolism and other phenotypes that are thought to confer a selective advantage for long-term persistence. Recently, clinical isolates of P. aeruginosa that hyperproduce agmatine (decarboxylated arginine) were cultured from individuals with CF. Sputum concentrations of this metabolite were also shown to correlate with disease severity. This raised the question of whether agmatine accumulation might also confer a selective advantage for P. aeruginosa during chronic colonization of the lung. Methodology and Results. We screened a library of P. aeruginosa CF clinical isolates and found that ~5 % of subjects harboured isolates with an agmatine hyperproducing phenotype. Agmatine accumulation was a direct result of mutations in aguA, encoding the arginine deiminase that catalyses the conversion of agmatine into various polyamines. We also found that agmatine hyperproducing isolates (aguA-) had increased tolerance to the cationic antibiotics gentamicin, tobramycin and colistin relative to their chromosomally complemented strains (aguA+). Finally, we revealed that agmatine diminishes IL-8 production by airway epithelial cells in response to bacterial infection, with a consequent decrease in neutrophil recruitment to the murine airways in an acute pneumonia model. Conclusion. These data highlight a potential new role for bacterial-derived agmatine that may have important consequences for the long-term persistence of P. aeruginosa in the CF airways.

10 May 2015 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
JDJoseph J. Dalluge
Joseph J. Dalluge
JMJennifer L. McCurtain
Jennifer L. McCurtain
AGAdam J. Gilbertsen
Adam J. Gilbertsen
KKKyle A. Kalstabakken
Kyle A. Kalstabakken
BWBryan J. Williams
Bryan J. Williams